What this deck covers
This deck focuses on Drug Recalls And Shortages, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.
Study Drug Recalls And Shortages in NAPLEX with focused flashcards that help you recognize the idea, recall the key rule, and apply it in practice-style prompts.
0% Complete
What is the most common root cause category for injectable drug shortages?
Tap card or press Space to flip
Manufacturing and quality problems (including remediation and capacity limits). Injectable shortages often stem from production issues like contamination or facility shutdowns, disrupting supply chains.
How well did you know it?
Card 1 / 25
Space to flip · ← / → to move · once flipped, → Got it · ← Still learning
This deck focuses on Drug Recalls And Shortages, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.
Work through these flashcards in short sessions. Try to answer each prompt before flipping the card, then revisit any cards you miss until the explanation feels automatic.
Answer: Manufacturing and quality problems (including remediation and capacity limits). Injectable shortages often stem from production issues like contamination or facility shutdowns, disrupting supply chains.
Answer: FDA Drug Shortages database. This database tracks ongoing shortages with details on causes, durations, and alternatives to guide clinical decision-making.
Answer: Quarantine (segregate and label as recalled; do not dispense). Quarantining segregates recalled products, minimizing risk of accidental use while awaiting further recall directives.
Answer: Reasonable probability of serious adverse health consequences or death. Class I recalls involve the highest risk level where exposure could lead to severe health issues or fatality, requiring immediate action.
Answer: Wholesale-level recall. Wholesale-level recalls stop distribution early in the supply chain, preventing further dissemination without reaching retail or consumers.
Answer: Quarantine and remove the affected lot from dispensing stock immediately. Immediate quarantine prevents dispensing, allowing time for manufacturer instructions on return or disposal to ensure safety.
Answer: Instruct the patient to stop using it and replace per recall guidance. Advising cessation and replacement follows recall protocols to protect patient health and comply with manufacturer or FDA guidance.
Answer: Potency/superpotent or subpotent product (assay out of specification). Potency deviations can lead to therapeutic failure or toxicity, violating quality standards and necessitating product removal.
Answer: Safety alert (or safety notification). Safety alerts notify users of device risks without formal recall, focusing on usage precautions rather than product removal.
Answer: Not likely to cause adverse health consequences. Class III recalls are for violations unlikely to cause health issues, often involving labeling or minor defects without patient risk.
Answer: Consumer-level recall. Consumer-level recalls extend to end-users, requiring notifications and returns to mitigate risks at the patient level.
Answer: FDA Enforcement Report. The Enforcement Report provides weekly updates on initiated recalls, including classifications and statuses for regulatory tracking.
Answer: Supply does not meet current or projected demand at the patient level. Shortages occur when production or distribution fails to meet demand, impacting access to essential medications for patient care.
Answer: Market withdrawal is minor/voluntary; recall addresses a legal violation. Market withdrawals are voluntary for non-violative issues, while recalls enforce legal corrections for FDA-regulated violations.
Answer: Removal or correction of a marketed product that violates FDA laws. FDA recalls address violations of laws to protect public health by removing or correcting unsafe or misbranded products from the market.
Answer: NDC, lot/batch number, strength, dosage form, and expiration date. These identifiers ensure precise matching to affected products, preventing dispensing of recalled items and ensuring accurate inventory checks.
Answer: Recall classification and consumer-level distribution with patient-level risk. High-risk classifications at consumer level necessitate outreach to inform patients and facilitate product returns or exchanges.
Answer: Retail-level recall. Retail-level recalls target pharmacies and retailers to remove products before reaching consumers, limiting distribution scope.
Answer: Class I. Class I poses the greatest risk, necessitating urgent public notification and rapid product removal to prevent serious harm or death.
Answer: Temporary or medically reversible harm is possible; serious harm unlikely. Class II recalls apply when health consequences are temporary or reversible, with low probability of serious harm, but still warrant removal.
Answer: Foreign particulate contamination. Particulates in injectables can cause embolisms or reactions, violating purity standards and triggering safety-based recalls.
Answer: FDA Recalls, Market Withdrawals, and Safety Alerts database. This database aggregates searchable recall information, enabling quick access to details for compliance and patient safety.
Answer: Product mix-up or mislabeling (incorrect product/strength in container). Mix-ups risk incorrect dosing or therapy, compromising safety and efficacy, thus requiring recalls to correct distribution errors.
Answer: Lack of sterility or microbial contamination risk. Sterility failures in injectables pose infection risks, prompting recalls to prevent microbial exposure in vulnerable patients.
Answer: Therapeutic interchange to an evidence-based alternative with monitoring. Interchanging to alternatives maintains therapy continuity, with monitoring to ensure efficacy and minimize adverse effects during shortages.